Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
NRG-LU003 is a National Cancer Institute and NRG Oncology clinical trial to study clinical benefit of 2nd or 3rd generation ALK inhibitor in patients who develop progression on a second-generation ALK inhibitor. Treatment will be based on genetic changes identified on their tumor biopsy. NRG-LU003 will be comparing a number of ALK inhibitors including lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib. These targeted therapies may stop the growth of tumor cells by blocking some of the enzymes needed for cancer growth. NRG-LU003 will also be comparing the chemotherapy drugs pemetrexed plus cisplatin, and or carboplatin to test if chemotherapy may work equal, better or worse in these patients. More specific details about the treatment can be found in the FAQ section below.
More information about this particular study is located on ClinicalTrials.gov
Find a study location
Are you interested in joining this study?
Want more information?
Additional information for the NRG Oncology LU003 trial can be found in the Patient Study Brochure
Your healthcare team is the best source for information about your treatment options, including the ability to help you make decision to participate in cancer clinical trials. Be sure to take the information you find to your doctor for discussion about possible studies and for questions and concerns.
Please talk to your healthcare team to see if there are other clinical studies that you may be a good fit for. Click here if you would like to view a more detailed chart of other studies available.
Below, you can find FAQs about clinical research and this particular clinical trial.
Doctors and researchers conduct a clinical study, also called a “clinical trial”, to find better ways to prevent, diagnose, or treat an illness. NRG Oncology is supported by the National Cancer Institute and runs clinical studies specifically for patients with cancer or to prevent cancer. Most clinical studies test something we know against something we don’t know. In all situations, these studies are strictly evaluated before they are allowed to be offered to any patient. The study is designed to answer the question that we do not know the answer to, so that current and future patients may have better treatments or information than what we currently have. There are different types of clinical studies that might be available for patients. For more information see “Types of Clinical Trials” and “Phases of Clinical Trials”.
At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.